Trelegy

(fluticasone / umeclidinium / vilanterol)
14 ACTUAT fluticasone furoate 0.1 MG/ACTUAT / umeclidinium 0.0625 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder Inhaler [Trelegy]14 ACTUAT fluticasone furoate 0.2 MG/ACTUAT / umeclidinium 0.0625 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder Inhaler [Trelegy]
View 2 more
NO BOXED WARNING

Dosage & administration

drug label

Trelegy prescribing information

samples

Request Trelegy samples

Online Sample Form
Learn More

prior authorization

Trelegy prior authorization resources

Most recent Trelegy prior authorization forms

View By Payer
Verified: Feb 07, 2024Kaiser Foundation Health Plan - Chronic High-Dose Opioid Therapy Prior Authorization Form Washington
Verified: Feb 01, 2024Highmark BCBS Northeastern NY - Medicare Prescription Drug Medication Request Form
Verified: Feb 01, 2024Highmark BCBS Northeastern NY - Short Acting Opioid Prior Authorization Form
Verified: Feb 01, 2024Highmark BCBS Western NY - Specialty Drug Prior Authorization Form
Verified: Feb 01, 2024Highmark BCBS Western NY - Non-Formulary Drug Coverage Prior Authorization Form

Most recent state uniform prior authorization forms

Verified: Feb 27, 2024Arizona - Uniform Prior Authorization Form
Verified: Feb 27, 2024Colorado - Uniform Prior Authorization Form
Verified: Feb 27, 2024Hawaii - Uniform Prior Authorization Form
Verified: Feb 27, 2024Illinois - Uniform Prior Authorization Form
Verified: Feb 27, 2024Indiana - Uniform Prior Authorization Form
Verified: Feb 27, 2024Louisiana - Uniform Prior Authorization Form
Verified: Feb 27, 2024Michigan - Uniform Prior Authorization Form
Verified: Feb 27, 2024Minnesota - Uniform Prior Authorization Form
Verified: Feb 27, 2024New Hampshire - Uniform Prior Authorization Form
Verified: Feb 27, 2024New Mexico - Uniform Prior Authorization Form
Verified: Feb 27, 2024Oregon - Uniform Prior Authorization Form
Verified: Feb 27, 2024Texas - Uniform Prior Authorization Form
Learn More

Benefits investigation

Patient Authorization Form - GSKForYou
Learn More

Reimbursement help (FRM)

Receive Assistance from an FRM Regarding Reimbursement Information
Learn More

financial assistance

Trelegy financial assistance options

Co-pay savings program

commercial only
Enroll in Patient Savings Program
Learn More

Foundation programs

under insured
no insurance
goverment insurance
65+
GSK Patient Assistance Program
Learn More

PubMed™ | Trelegy

Trelegy PubMed™ News

patient education

Trelegy patient education

Getting started on Trelegy

Instructions For Use: COPD
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Instructions For Use: Asthma
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Instructions For Use (Spanish): COPD & Asthma
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
To share resource; ask patient to:
1.Pull out phone
2.Open camera
3.Scan QR code with camera
4.Tap link

Patient toolkit

About Trelegy Ellipta: COPD
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Doctor Discussion Guide: COPD
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Stories: COPD
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
About Trelegy Ellipta: Asthma
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Stories: Asthma
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Using Trelegy Ellipta
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Resources: COPD
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Resources: Asthma
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Doctor Discussion Guide: Asthma
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Asthma Action Plan
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Asthma Control Test
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Asthma Control Test: Spanish
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
COPD Assesment Test
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Learn More

people also ask

Trelegy FAQs

8.1 Pregnancy Risk SummaryInsufficient data are available on the use of TRELEGY ELLIPTA or its individual components (fluticasone furoate, umeclidinium, and vilanterol) in pregnant women to determine a drug-associated risk. Animal studies showed no adverse effects on embryofetal development for these components at exposures approximately 4.5 to 200 times the maximum recommended daily inhalation doses in adults.
8.2 Lactation Risk SummaryNo information is available on the presence of these components in human milk, their effects on the breastfed child, or milk production. Umeclidinium was detected in the plasma of offspring of lactating rats treated with umeclidinium, suggesting its presence in maternal milk.
8.4 Pediatric UseTRELEGY ELLIPTA is not approved for use in pediatric patients, and its safety and efficacy in pediatric patients have not been established.
8.5 Geriatric UseNo dosage adjustment is necessary for geriatric patients, but greater sensitivity in some older individuals cannot be ruled out.
8.6 Hepatic ImpairmentTRELEGY ELLIPTA has not been studied in subjects with hepatic impairment. Information on the individual components is provided.
8.7 Renal ImpairmentTRELEGY ELLIPTA has not been studied in subjects with renal impairment. Information on the individual components is provided.
FAQ Data Source